HemaSphere Podcast

HemaSphere Journal

HemaSphere is the official online, open access journal of the European Hematology Association (EHA). HemaSphere publishes exciting basic, translational, and clinical research in hematology. We are pleased to introduce our new podcast series where our host and guest speakers exchange ideas about select HemaSphere publications. Spend some time with us and enjoy casual and insightful discussions about hematology research. Listen to the stories behind the papers. HemaSphere is always accessible; our full range of open access publications is available at www.hemaspherejournal.com. 2025 JIF 11.4

  1. 2d ago

    When Treatment Works, but the Numbers Don't - Pierre Sujobert

    This episode examines the gap between improving survival and continuing disease burden in hematological malignancies. Dr Pierre Sujobert discusses with host Dr Charles de Bock epidemiological patterns across hematological malignancies, including rising incidence in multiple myeloma, non-Hodgkin lymphomas, and acute myeloid leukemia. He also considers environmental and occupational exposures, the value of locally focused research, and the importance of taking patients’ work histories seriously. This episode is relevant to hematology researchers and clinicians studying treatment outcomes, prevention, and population health. Original article: Therapeutic success and epidemiological failure in hematology SEER Data & Software: https://seer.cancer.gov/data-software/ Thoughts on the podcast? Fill out our feedback form. 00:00 - Introducing the guest and the epidemiological paradox 04:12 - What SEER data reveal about survival, incidence, and mortality 06:08 - Five patterns across hematological malignancies 09:01 - Diagnostic bias and how far U.S. data can be generalized 12:01 - Environmental and occupational exposures behind rising incidence 14:53 - Local research and the role of hematologists in pesticide advocacy 18:12 - Why clinicians should document patients’ occupational histories 21:19 - Measuring environmental risk and interpreting a risk of 1.4 23:31 - Research opportunities: glyphosate, microbiota, and cancer biology 26:50 - Why prevention and treatment should go hand in hand 29:31 - Writing about science, advocacy, and public health

  2. Oct 21

    CAR T From Within - Vilcot, Brugère, Fuentealba, Houot

    Could making CAR T cells directly inside the patient change how treatment is delivered? Scientific Editor Dr Charles De Bock joins Prof Roch Houot, Dr Jaime Fuentealba, François Vilcot, PharmD, and Carole-Anne Brugère, PharmD, to explore the promise and challenges of in vivo CAR therapy. They compare delivery approaches, examine safety and targeting, and discuss potential gains in access alongside uncertainty over costs. Listen for a multidisciplinary perspective on what comes next. Read the referenced Review Article here: https://bit.ly/4d1mfjP Key topics How in vivo CAR therapy differs from conventional CAR T manufacturingLentiviral vectors and lipid nanoparticles: targeting, persistence, and safety, including the need for long-term monitoringClinical translation, scalability, and why simpler delivery may not mean lower pricesEurope’s role in development and lessons from writing a multidisciplinary review Timestamps 00:00 — Why in vivo CAR is attracting attention now 02:37 — What it means to manufacture CAR T cells inside the patient 05:29 — Three layers of specificity for lentiviral delivery 10:08 — Why modern lentiviral vectors are safer than early gene therapy vectors 14:41 — How lipid nanoparticles can target T cells and avoid the liver 16:26 — Whether transient CAR expression can still be therapeutic 19:10 — Choosing between lentiviral vectors and lipid nanoparticles 22:53 — The hardest unsolved problem: balancing efficacy, safety, and scalability 23:18 — Site-specific gene editing and TRAC locus insertion 26:21 — Industry momentum and whether in vivo CAR can lower cost 28:40 — Europe’s opportunity in clinical translation 31:23 — What to expect from upcoming ASH and other conference data 35:05 — How the multidisciplinary review was scoped and organized 37:09 — Why figures were designed early in the writing process 39:57 — Advice for PhD students writing a review in a fast-moving field

About

HemaSphere is the official online, open access journal of the European Hematology Association (EHA). HemaSphere publishes exciting basic, translational, and clinical research in hematology. We are pleased to introduce our new podcast series where our host and guest speakers exchange ideas about select HemaSphere publications. Spend some time with us and enjoy casual and insightful discussions about hematology research. Listen to the stories behind the papers. HemaSphere is always accessible; our full range of open access publications is available at www.hemaspherejournal.com. 2025 JIF 11.4